Work

Pbi30 Budget-impact and Cost-effectiveness of Tildrakizumab for the Treatment of Moderate-to-severe Plaque Psoriasis From a Us Health Plan Perspective

Year: 2019

Type: conference-abstract

Source: Value in Health

DOI: 10.1016/j.jval.2019.04.112

Authors: J. Carrico, X. Jia, Y. Zhao, J. Zhang, T.H. Brodtkorb, A.B. Mendelsohn, S. Lowry, J.J. Wu, S.R. Feldman, A.W. Armstrong

Institutions: RTI Health Solutions, Kaiser Permanente, Los Angeles Medical Center, Wake Forest University Health Sciences, Wake Forest University

Language: English

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2953396986

Cites:

Cited by:

Related to: 10